HealthcareServices

Prothrombin Complex Concentrate Market Insights Report: Opportunities and Drivers 2030

March 2, 2026March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the prothrombin complex concentrate market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Prothrombin Complex Concentrate Market between 2026 and 2030?

The market for prothrombin complex concentrate has demonstrated substantial growth in recent years. Its value is projected to rise from $1.38 billion in 2025 to $1.48 billion in 2026, at a compound annual growth rate (CAGR) of 7.4%. This historical expansion can be attributed to factors such as the increasing prevalence of coagulation disorders, the expansion of emergency care infrastructure, the availability of plasma-derived therapies, a rise in surgical procedure volumes, and the growing use of anticoagulant medications.

The prothrombin complex concentrate market is projected for substantial expansion in the coming years. This market is forecast to reach $1.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.2%. This expansion during the projection period stems from several factors, including a heightened need for swift coagulation treatments, escalating investments in developing recombinant factors, an increase in trauma care infrastructure, an intensified emphasis on ensuring patient safety in anticoagulant treatments, and the wider acceptance of standardized bleeding management guidelines. Key developments anticipated over the forecast timeframe involve the growing acceptance of four-factor PCC products, an increased application of PCC for quick reversal of anticoagulation, a heightened requirement for immediate bleeding management solutions, the broadened availability of recombinant coagulation products, and a stronger emphasis on fast-acting hemostatic treatments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23488&type=smp

Which Drivers Are Expected To Impact The Prothrombin Complex Concentrate Market During The Forecast Period?

The expansion of the prothrombin complex concentrate market is anticipated to be spurred by the rising occurrence of bleeding disorders. These conditions, characterized by inadequate blood clotting and subsequent excessive bleeding due to deficient or faulty clotting factors or platelets, are becoming more common. This increase is primarily attributed to a greater incidence of genetic disorders such as hemophilia, a surge in liver disease cases, the expanding application of anticoagulant medications, and a higher frequency of vitamin K deficiencies. Prothrombin complex concentrate offers a solution by quickly restoring clotting factors, which are crucial for effective blood coagulation and stopping bleeding. For example, a report from the World Federation of Hemophilia, published in October 2024, revealed that in 2023, there were 179,703 documented cases of hemophilia A. Of these, 162,040 cases, accounting for 90%, were male, 6,990 cases were female, and 10,673 cases, or 6%, did not specify the patient’s sex. Consequently, the growing prevalence of bleeding disorders is a key factor propelling the growth of the prothrombin complex concentrate market.

Which Segments Are Driving Activity In The Prothrombin Complex Concentrate Market?

The prothrombin complex concentrate market covered in this report is segmented –

1) By Product: 3-Factor Prothrombin Complex Concentrates, 4-Factor Prothrombin Complex Concentrates, Other Products

2) By Indication: Haemorrhagic Episodes In Factor IX Deficiency (Haemophilia B), Trauma, Life-Threatening Coagulopathy With Acute Bleeding, Warfarin-Associated Acute, Life-Threatening Bleeding, Non-Warfarin Anticoagulant Reversal With Acute Bleeding

3) By Route Of Administration: Intravenous, Intravenous Infusion Variants, Intravenous Bolus Administration

4) By End-Use: Hospital And Ambulatory Surgical Centers, Specialty Clinics, Other End Users

Subsegments:

1) By 3-Factor PCC Type: Low-Dose 3-Factor Prothrombin Complex Concentrates (PCC), High-Dose 3-Factor Prothrombin Complex Concentrates (PCC), Lyophilized 3-Factor Prothrombin Complex Concentrates (PCC)

2) By 4-Factor PCC Typ: Low-Dose 4-Factor Prothrombin Complex Concentrates (PCC), High-Dose 4-Factor Prothrombin Complex Concentrates (PCC), Activated 4-Factor Prothrombin Complex Concentrates (PCC)

3) By Other Products: Recombinant Coagulation Factor Complexes, Plasma-Derived Coagulation Factor Complexes, Combination Therapy Products

How Are New Market Trends Shaping The Landscape Of The Prothrombin Complex Concentrate Market?

Key companies in the prothrombin complex concentrate market are actively developing novel formulations, like lyophilized powder, to improve stability, optimize storage, and simplify administration. This lyophilized powder is a freeze-dried preparation that removes water, thereby extending its shelf life and preserving its potency. This allows for improved storage conditions and rapid reconstitution for emergency use. For instance, in July 2023, Octapharma USA Inc., a US-based biotechnology company, obtained FDA approval for Balfaxar, a four-factor prothrombin complex concentrate (4F-PCC) for urgent warfarin reversal during surgeries and invasive procedures. This approval was granted based on the LEX-209 trial, which revealed 94.6% hemostatic efficacy, demonstrating its effectiveness comparable to Kcentra. This progression emphasizes the industry’s dedication to advancing coagulation therapies to enhance patient outcomes in critical care situations.

Which Major Firms Are Strengthening Their Position In The Prothrombin Complex Concentrate Market?

Major companies operating in the prothrombin complex concentrate market are Pfizer Inc., Takeda Pharmaceutical Company Limited, CSL Behring GmbH, Baxter International Inc, Grifols S.A., Octapharma AG, Kedrion S.p.A, Green Cross Corporation, Shanghai RAAS Blood Products Co. Ltd, LFB Group, Hualan Biological Engineering Chongqing Co. Ltd., Sanquin Blood Supply Foundation, Bio Products Laboratory Ltd BPL, Prothya Biosolutions B.V., China Biologic Products Holdings Inc., Intas Pharmaceuticals Ltd, Biotest AG, Octapharma Plasma, Kamada Ltd, SK Plasma Co. Ltd, Reliance Life Sciences, Bharat Serums And Vaccines Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/prothrombin-complex-concentrate-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Prothrombin Complex Concentrate Market?

North America was the largest region in the prothrombin complex concentrate market in 2025. The regions covered in the prothrombin complex concentrate market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Prothrombin Complex Concentrate Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23488&type=smp

Browse Through More Reports Similar to the Global Prothrombin Complex Concentrate Market 2026, By The Business Research Company

Juice Concentrates Market Report 2026

https://www.thebusinessresearchcompany.com/report/juice-concentrates-global-market-report

Bilirubin Blood Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/bilirubin-blood-test-global-market-report

Proteomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/proteomics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795